Title :

No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months

Author(s) :

Pagniez, Dominique [Auteur]
Service de Néphrologie et Transplantation rénale [CHRU-lille]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Boulanger, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995
Lessore De Sainte Foy, Celia [Auteur]
Service de Néphrologie et Transplantation rénale [CHRU-lille]
BEUSCART, Jean-Baptiste [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Journal title :

BMC nephrology

Abbreviated title :

BMC Nephrol.

Volume number :

18

Publication date :

2017-08-31

ISSN :

1471-2369

Keyword(s) :

Mesh:Kidney Failure
Mesh:Chronic/diagnosis
Mesh:Female
Mesh:Biological Transport/physiology
Mesh:Middle Aged
Mesh:Glucose Solution
Mesh:Hypertonic/administration & dosage*
Mesh:Biological Transport/drug effects
Mesh:Peritoneal Dialysis/methods*
Mesh:Kidney Failure
Mesh:Chronic/therapy*
Mesh:Cohort Studies
Mesh:Aged
Mesh:Treatment Outcome
Mesh:Time Factors
Mesh:Male
Mesh:Adult
Mesh:Follow-Up Studies
Mesh:Peritoneal Dialysis/trends*
Mesh:Kidney Failure
Mesh:Chronic/metabolism*
Mesh:Humans
Peritoneal equilibration test
Peritoneal dialysis
Small-solute transport
Glucose exposure
Glucose sparing

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been ...
Show more >Background Glucose is widely used as an osmotic agent in peritoneal dialysis (PD), but exerts untoward effects on the peritoneum. The potential protective effect of a reduced exposure to hypertonic glucose has never been investigated. Methods The cohort of PD patients attending our center which tackled the challenge of a restricted use of hypertonic glucose solutions has been prospectively followed since 1992. Small-solute transport was assessed using an equivalent of the glucose peritoneal equilibration test after 6 months, and then every year. Study was stopped on July 1st, 2008, before use of biocompatible solutions. Repeated measures in patients treated with PD for 54 months were analyzed by using (1) the slopes of the linear regression for D4/D0 ratios over time computed for each individual, and (2) a linear mixed model. Results In the study period, 44 patients were treated for a total of 2376 months, 2058 without hypertonic glucose. There was one episode of peritoneal infection every 18 patient-months. The mean of slopes of the linear regression for D4/D0 ratios was found to be significantly positive (Student’s test, p < .001) and the results of the mixed model reflected a similar significant increase for D4/D0 ratios over time. These results reflected a significant decrease of small-solute transport. Conclusion In this large series, minimizing the use of hypertonic glucose solutions was associated in patients on long term PD with an overall decrease of small-solute transport within 54 months, despite a high rate of peritoneal infection.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Research team(s) :

Glycation from inflammation to aging

Submission date :

2019-03-01T15:17:27Z
2020-03-20T16:30:53Z
2020-03-24T14:51:46Z